Chawnshang Chang

List of Publications by Year
in descending order

343 papers	23,037 citations	7568 77 h-index	12597 132 g-index
355 all docs	355 docs citations	355 times ranked	20095 citing authors

#	Article	IF	Citations
1	Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERÎ²/Hif2-Î± signaling. Cancer Letters, 2022, 524, 15-28.	7.2	20
2	Targeted activation of androgen receptor signaling in the periosteum improves bone fracture repair. Cell Death and Disease, 2022, 13, 123.	6.3	3
3	High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling. Cell Death Discovery, 2022, 8, 128.	4.7	9
4	Targeting circDGKD Intercepts TKIâ€™s Effects on Up-Regulation of Estrogen Receptor Î² and Vasculogenic Mimicry in Renal Cell Carcinoma. Cancers, 2022, 14, 1639.	3.7	5
5	ASC-J9Â® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling. Journal of Experimental and Clinical Cancer Research, 2021, 40, 3.	8.6	10
6	Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death. Cell Death and Disease, 2021, 12, 68.	6.3	9
7	Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR. Oncogene, 2021, 40, 1674-1689.	5.9	23
8	Androgen receptor decreases renal cell carcinoma bone metastases via suppressing the osteolytic formation through altering a novel circEXOC7 regulatory axis. Clinical and Translational Medicine, 2021, 11, e353.	4.0	19
9	Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARÎ³/MMP-9 signals. Cell Death and Differentiation, 2021, 28, 2145-2159.	11.2	32
10	Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression. Cell Death and Disease, 2021, 12, 855.	6.3	10
11	R-2HG downregulates ERÎ± to inhibit cholangiocarcinoma via the FTO/m6A-methylated ERÎ±/miR16-5p/YAP1 signal pathway. Molecular Therapy - Oncolytics, 2021, 23, 65-81.	4.4	14
12	Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression. Oncogene, 2020, 39, 530-545.	5.9	24
13	Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Cî±i protein/MAPK/MMP9 intracellular signaling. Oncogene, 2020, 39, 574-586.	5.9	27
14	Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFÎ²1/p-Smad2/3 signaling. Cancer Letters, 2020, 472, 151-164.	7.2	43
15	Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression. Oncogene, 2020, 39, 1891-1903.	5.9	11
16	The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer. Cell Death and Disease, 2020, 11, 807.	6.3	26
17	Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity. Cancer Letters, 2020, 495, 100-111.	7.2	20
18	Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer. Cell Death and Disease, 2020, 11, 942.	6.3	10

#	Article	IF	Citations
19	Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner. Oncogene, 2020, 39, 6677-6691.	5.9	4
20	The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. Nature Communications, 2020, 11, 2689.	12.8	41
21	Targeting the ERÎ²/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC. Cell Death and Disease, 2020, 11, 367.	6.3	21
22	Olaparib and enzalutamide synergistically suppress HCC progression via the ARâ€mediated miRâ€146aâ€5p/BRCA1 signaling. FASEB Journal, 2020, 34, 5877-5891.	0.5	9
23	The miR-92a-2-5p in exosomes from macrophages increases liver cancer cells invasion via altering the AR/PHLPP/p-AKT/Î²-catenin signaling. Cell Death and Differentiation, 2020, 27, 3258-3272.	11.2	54
24	Androgen receptorâ€regulated circ <scp>FNTA</scp> activates <scp>KRAS</scp> signaling to promote bladder cancer invasion. EMBO Reports, 2020, 21, e48467.	4.5	60
25	Estrogen receptor Î± promotes lung cancer cell invasion via increase of and crossâ€talk with infiltrated macrophages through the CCL2/CCR2/MMP9 and CXCL12/CXCR4 signaling pathways. Molecular Oncology, 2020, 14, 1779-1799.	4.6	33
26	Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. Cancers, 2020, 12, 831.	3.7	11
27	Targeting the estrogen receptor alpha (ERÎ±)-mediated circ-SMG1.72/miR-141-3p/Gelsolin signaling to better suppress the HCC cell invasion. Oncogene, 2020, 39, 2493-2508.	5.9	33
28	Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naÃ¯ve prostate cancer cells. Aging, 2020, 12, 17694-17712.	3.1	2
29	ASC-J9Â® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-ÎºB survival signals. Journal of Experimental and Clinical Cancer Research, 2019, 38, 275.	8.6	18
30	Deficiency in Androgen Receptor Aggravates the Depressive-Like Behaviors in Chronic Mild Stress Model of Depression. Cells, 2019, 8, 1021.	4.1	24
31	LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling. Nature Communications, 2019, 10, 2571.	12.8	153
32	The Protective Roles of Estrogen Receptor Î² in Renal Calcium Oxalate Crystal Formation via Reducing the Liver Oxalate Biosynthesis and Renal Oxidative Stress-Mediated Cell Injury. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-17.	4.0	26
33	Androgen receptor regulates ASS1P3/miR-34a-5p/ASS1 signaling to promote renal cell carcinoma cell growth. Cell Death and Disease, 2019, 10, 339.	6.3	24
34	Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR-185-5p/CSF-1 signals. Cell Death and Disease, 2019, 10, 275.	6.3	36
35	Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression. Cell Death and Disease, 2019, 10, 37.	6.3	74
36	Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression. EBioMedicine, 2019, 40, 504-516.	6.1	21

#	Article	IF	Citations
37	Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. Oncogene, 2019, 38, 4875-4884.	5.9	27
38	LncRNA PCAT1 activates AKT and NF-Î²B signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKÎ± complex. Nucleic Acids Research, 2019, 47, 4211-4225.	14.5	129
39	Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth. Cancer Letters, 2019, 442, 483-490.	7.2	10
40	Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype. Cancer Letters, 2019, 444, 175-187.	7.2	46
41	Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9Â® led to increase docetaxel sensitivity via suppressing the p21 expression. Cancer Letters, 2019, 444, 35-44.	7.2	21
42	ASC-J9 Â® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3. Cancer Letters, 2018, 425, 21-30.	7.2	27
43	ERÎ²-Mediated Alteration of circATP2B1 and miR-204-3p Signaling Promotes Invasion of Clear Cell Renal Cell Carcinoma. Cancer Research, 2018, 78, 2550-2563.	0.9	66
44	Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor Î²/IL-1/c-MET signals. Cancer Letters, 2018, 430, 215-223.	7.2	29
45	TR4 nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression. Cell Death and Disease, 2018, 9, 283.	6.3	18
46	Preclinical studies using miRâ€32â€5p to suppress clear cell renal cell carcinoma metastasis via altering the miRâ€32â€5p/TR4/HGF/Met signaling. International Journal of Cancer, 2018, 143, 100-112.	5.1	38
47	Androgen receptor (AR) degradation enhancer ASC-J9 Â® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth. Cancer Letters, 2018, 417, 182-191.	7.2	34
48	A Festschrift in Honor of Edward M. Messing, MD, FACS. Bladder Cancer, 2018, 4, S1-S43.	0.4	0
49	ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis. Cancer Letters, 2018, 439, 47-55.	7.2	35
50	Targeting newly identified ERÎ²/TGFâ€Î²1/SMAD3 signals with the FDAâ€approved antiâ€estrogen Faslodex or an ERÎ² selective antagonist in renal cell carcinoma. Molecular Oncology, 2018, 12, 2055-2071.	4.6	21
51	Estrogen receptor Î² promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network. Oncogene, 2018, 37, 5037-5053.	5.9	93
52	TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals. Oncogene, 2018, 37, 5901-5912.	5.9	33
53	Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. Cancer Letters, 2017, 394, 1-12.	7.2	186
54	Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Â® to Suppress Enzalutamide-resistant Prostate Cancer Progression. European Urology, 2017, 72, 835-844.	1.9	103

#	Article	IF	Citations
55	C1QBP Regulates YBX1 to Suppress the Androgen Receptor (AR)-Enhanced RCC Cell Invasion. Neoplasia, 2017, 19, 135-144.	5.3	15
56	Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Cancer Letters, 2017, 398, 62-69.	7.2	34
57	Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer. Cancer Letters, 2017, 397, 133-143.	7.2	33
58	Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma. Nature Communications, 2017, 8, 918.	12.8	60
59	Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression. Cancer Letters, 2017, 408, 155-163.	7.2	26
60	LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death and Differentiation, 2017, 24, 1502-1517.	11.2	131
61	Sorafenib with ASC-J9^{Â®}synergistically suppresses the HCC progressionviaaltering the pSTAT3-CCL2/Bcl2 signals. International Journal of Cancer, 2017, 140, 705-717.	5.1	25
62	YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth. Oncotarget, 2017, 8, 115054-115067.	1.8	24
63	TR2 and TR4 Orphan Nuclear Receptors. Current Topics in Developmental Biology, 2017, 125, 357-373.	2.2	26
64	ASC-J9Â®, and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals. Cancer Letters, 2016, 376, 377-386.	7.2	25
65	ASC-J9Â® suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Cancer Letters, 2016, 379, 154-160.	7.2	44
66	The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals. EBioMedicine, 2016, 12, 55-67.	6.1	66
67	Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1â†'Androgen Receptorâ†'HIF1Î±â†'VEGFa Signals. Molecular Cancer Therapeutics, 2016, 15, 1943-1951.	4.1	21
68	Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells. Molecular Carcinogenesis, 2016, 55, 2278-2290.	2.7	39
69	Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. Cancer Letters, 2016, 373, 45-56.	7.2	75
70	CREB/GSK-3Î² signaling pathway regulates the expression of TR4 orphan nuclear receptor gene. Molecular and Cellular Endocrinology, 2016, 423, 22-29.	3.2	8
71	Androgen receptor (AR) in cardiovascular diseases. Journal of Endocrinology, 2016, 229, R1-R16.	2.6	58
72	Targeting Androgen Receptor (AR)â†'IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression. Molecular Cancer Therapeutics, 2016, 15, 731-742.	4.1	49

#	Article	IF	Citations
73	Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells. Oncotarget, 2016, 7, 46448-46465.	1.8	22
74	New therapy with ASC-J9Â® to suppress the prostatitis via altering the cytokine CCL2 signals. Oncotarget, 2016, 7, 66769-66775.	1.8	6
75	Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERÎ²/CCL2/CCR2 EMT/MMP9 signals. Oncotarget, 2016, 7, 7842-7855.	1.8	72
76	TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth. Oncotarget, 2016, 7, 32088-32099.	1.8	16
77	Testicular orphan nuclear receptor 4 is associated with the radio-sensitivity of prostate cancer. Prostate, 2015, 75, 1632-1642.	2.3	11
78	TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures. Oncotarget, 2015, 6, 25726-25740.	1.8	13
79	TR4 Nuclear Receptor Different Roles in Prostate Cancer Progression. Frontiers in Endocrinology, 2015, 6, 78.	3.5	12
80	The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status. Neoplasia, 2015, 17, 339-347.	5.3	8
81	BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts. International Journal of Oncology, 2015, 47, 719-727.	3.3	44
82	Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11â†'miRNAâ€541â†'androgen receptor (AR)â†'MMP9 signaling. Molecular Oncology, 2015, 9, 44-57.	4.6	74
83	Proteomic analysis of urethral protein expression in an estrogen receptor Î±-deficient murine model of stress urinary incontinence. World Journal of Urology, 2015, 33, 1635-1643.	2.2	6
84	Abnormal Mitochondrial Function and Impaired Granulosa Cell Differentiation in Androgen Receptor Knockout Mice. International Journal of Molecular Sciences, 2015, 16, 9831-9849.	4.1	30
85	Antiâ€androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cellsÂâ†'Âandrogen receptor (AR)Ââ†'ÂmiRNA32 signals. Molecular Oncology, 2015, 9, 1241-1251.	4.6	47
86	TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression. Molecular Cancer Therapeutics, 2015, 14, 1445-1453.	4.1	17
87	Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating macrophages with alteration of the TIMP-1/MMP2/MMP9 signals. Molecular Cancer, 2015, 14, 16.	19.2	32
88	TR4 nuclear receptor promotes prostate cancer metastasis via upregulation of CCL2/CCR2 signaling. International Journal of Cancer, 2015, 136, 955-964.	5.1	33
89	Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression. Molecular Cancer Therapeutics, 2015, 14, 2586-2594.	4.1	34
90	Infiltrating neutrophils promote renal cell carcinoma (RCC) proliferation via modulating androgen receptor (AR)â€‰â†'â€‰c-Myc signals. Cancer Letters, 2015, 368, 71-78.	7.2	23

#	Article	IF	Citations
91	Androgen Receptor Promotes Abdominal Aortic Aneurysm Development via Modulating Inflammatory Interleukin-1Î± and Transforming Growth Factor-Î²1 Expression. Hypertension, 2015, 66, 881-891.	2.7	37
92	Stromal Androgen Receptor Roles in the Development of Normal Prostate, Benign Prostate Hyperplasia, and Prostate Cancer. American Journal of Pathology, 2015, 185, 293-301.	3.8	61
93	TR4 nuclear receptor enhances prostate cancer initiation via altering the stem cell population and EMT signals in the PPARG-deleted prostate cells. Oncoscience, 2015, 2, 142-150.	2.2	12
94	Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-Î²1/Smad/MMP9 signals. Oncotarget, 2015, 6, 12326-12339.	1.8	45
95	Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population. Oncotarget, 2015, 6, 14179-14190.	1.8	72
96	TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFÎ²R2/p-Smad3 signals. Oncotarget, 2015, 6, 15397-15409.	1.8	32
97	Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasionviaaltering the CCL5/HIF2Î±/androgen receptor signals. Oncotarget, 2015, 6, 27555-27565.	1.8	33
98	Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. Oncotarget, 2015, 6, 31203-31215.	1.8	37
99	Tumor microenvironment B cells increase bladder cancer metastasisviamodulation of the IL-8/androgen receptor (AR)/MMPs signals. Oncotarget, 2015, 6, 26065-26078.	1.8	83
100	Infiltrating neutrophils increase bladder cancer cell invasionviamodulation of androgen receptor (AR)/MMP13 signals. Oncotarget, 2015, 6, 43081-43089.	1.8	41
101	Urethral Dysfunction in Female Mice with Estrogen Receptor Î² Deficiency. PLoS ONE, 2014, 9, e109058.	2.5	3
102	The Wedelolactone Derivative Inhibits Estrogen Receptor-Mediated Breast, Endometrial, and Ovarian Cancer Cells Growth. BioMed Research International, 2014, 2014, 1-11.	1.9	19
103	TR4 nuclear receptor functions as a tumor suppressor for prostate tumorigenesis via modulation of DNA damage/repair system. Carcinogenesis, 2014, 35, 1399-1406.	2.8	26
104	Minireview: Pathophysiological Roles of the TR4 Nuclear Receptor: Lessons Learned From Mice Lacking TR4. Molecular Endocrinology, 2014, 28, 805-821.	3.7	23
105	TR4 promotes fatty acid synthesis in 3T3â€L1 adipocytes by activation of pyruvate carboxylase expression. FEBS Letters, 2014, 588, 3947-3953.	2.8	6
106	Androgen Receptor Enhances Kidney Stone-CaOx Crystal Formation via Modulation of Oxalate Biosynthesis & Oxidative Stress. Molecular Endocrinology, 2014, 28, 1291-1303.	3.7	48
107	Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. Endocrine-Related Cancer, 2014, 21, R165-R182.	3.1	130
108	Determination of androgen receptor degradation enhancer ASC-J9Â® in mouse sera and organs with liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 117-122.	2.8	19

#	Article	IF	Citations
109	New Therapy via Targeting Androgen Receptor in Monocytes/Macrophages to Battle Atherosclerosis. Hypertension, 2014, 63, 1345-1353.	2.7	40
110	Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treatment Reviews, 2014, 40, 31-40.	7.7	85
111	Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation. Tumor Biology, 2014, 35, 1881-1890.	1.8	42
112	Identification of a new androgen receptor (AR) coâ€regulator BUD31 and related peptides to suppress wildâ€type and mutated ARâ€mediated prostate cancer growth via peptide screening and Xâ€ray structure analysis. Molecular Oncology, 2014, 8, 1575-1587.	4.6	51
113	Concise Review: Androgen Receptor Differential Roles in Stem/Progenitor Cells Including Prostate, Embryonic, Stromal, and Hematopoietic Lineages. Stem Cells, 2014, 32, 2299-2308.	3.2	39
114	ASC-J9 Suppresses Renal Cell Carcinoma Progression by Targeting an Androgen Receptorâ€“Dependent HIF2Î±/VEGF Signaling Pathway. Cancer Research, 2014, 74, 4420-4430.	0.9	77
115	Anabolic androgens affect the competitive interactions in cell migration and adhesion between normal mouse urothelial cells and urothelial carcinoma cells. Biochemical and Biophysical Research Communications, 2014, 452, 322-327.	2.1	1
116	Reply by the Authors. Urology, 2014, 84, 735.	1.0	0
117	Androgen Receptor Roles in Insulin Resistance and Obesity in Males: The Linkage of Androgen-Deprivation Therapy to Metabolic Syndrome. Diabetes, 2014, 63, 3180-3188.	0.6	61
118	Differential roles of PPARÎ³ vs TR4 in prostate cancer and metabolic diseases. Endocrine-Related Cancer, 2014, 21, R279-R300.	3.1	16
119	The Expression and Evaluation of Androgen Receptor in Human Renal Cell Carcinoma. Urology, 2014, 83, 510.e19-510.e24.	1.0	47
120	Androgen receptor enhances cell adhesion and decreases cell migration via modulating Î²1-integrin-AKT signaling in hepatocellular carcinoma cells. Cancer Letters, 2014, 351, 64-71.	7.2	48
121	Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. Clinical Investigation, 2014, 4, 935-950.	0.0	25
122	Recent advances in the study of testicular nuclear receptor 4. Journal of Zhejiang University: Science B, 2013, 14, 171-177.	2.8	11
123	New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells. American Journal of Pathology, 2013, 182, 460-473.	3.8	73
124	Androgen receptor enhances entosis, a nonâ€apoptotic cell death, through modulation of Rho/ROCK pathway in prostate cancer cells. Prostate, 2013, 73, 1306-1315.	2.3	25
125	Androgen receptor in human prostate cancer-associated fibroblasts promotes prostate cancer epithelial cell growth and invasion. Medical Oncology, 2013, 30, 674.	2.5	62
126	Targeting Thymic Epithelia AR Enhances T-Cell Reconstitution and Bone Marrow Transplant Grafting Efficacy. Molecular Endocrinology, 2013, 27, 25-37.	3.7	38

#	Article	IF	Citations
127	Decreased Tumorigenesis and Mortality from Bladder Cancer in Mice Lacking Urothelial Androgen Receptor. American Journal of Pathology, 2013, 182, 1811-1820.	3.8	104
128	Androgen Receptor Roles in the Development of Benign Prostate Hyperplasia. American Journal of Pathology, 2013, 182, 1942-1949.	3.8	124
129	Loss of androgen receptor promotes adipogenesis but suppresses osteogenesis in bone marrow stromal cells. Stem Cell Research, 2013, 11, 938-950.	0.7	21
130	Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. Hepatology, 2013, 57, 1550-1563.	7.3	58
131	Suppression of Androgen Receptor Enhances the Self-renewal of Mesenchymal Stem Cells Through Elevated Expression of EGFR. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1222-1234.	4.1	27
132	Higher Expression of Peroxisome Proliferator-activated Receptor Î³ or Its Activation byÂAgonist Thiazolidinedione-rosiglitazone Promotes Bladder Cancer CellÂMigration andÂInvasion. Urology, 2013, 81, 1109.e1-1109.e6.	1.0	26
133	Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9Â® Lead to Promotion versus Suppression of Prostate Cancer Metastasis. Journal of Biological Chemistry, 2013, 288, 19359-19369.	3.4	106
134	Targeting Stromal Androgen Receptor Suppresses Prolactin-Driven Benign Prostatic Hyperplasia (BPH). Molecular Endocrinology, 2013, 27, 1617-1631.	3.7	37
135	New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. Journal of Molecular Cell Biology, 2013, 5, 14-26.	3.3	91
136	Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. Carcinogenesis, 2013, 34, 257-267.	2.8	32
137	Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6â†'Androgen Receptorâ†'TGF-Î²â†'MMP-9 Signals. Molecular Cancer Therapeutics, 2013, 12, 1026-1037.	4.1	86
138	Androgen Receptor (AR) Physiological Roles in Male and Female Reproductive Systems: Lessons Learned from AR-Knockout Mice Lacking AR in Selective Cells1. Biology of Reproduction, 2013, 89, 21.	2.7	114
139	Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9^{Â®}to better battle prostate cancer progression. OncoImmunology, 2013, 2, e26853.	4.6	19
140	Infiltrating Macrophages Promote Prostate Tumorigenesis via Modulating Androgen Receptor-Mediated CCL4â€"STAT3 Signaling. Cancer Research, 2013, 73, 5633-5646.	0.9	125
141	Neuronal Androgen Receptor Regulates Insulin Sensitivity via Suppression of Hypothalamic NF-ÎºBâ€"Mediated PTP1B Expression. Diabetes, 2013, 62, 411-423.	0.6	67
142	Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2â€induced STAT3 activation. EMBO Molecular Medicine, 2013, 5, 1383-1401.	6.9	199
143	Increased Chemosensitivity via Targeting Testicular Nuclear Receptor 4 (TR4)-Oct4-Interleukin 1 Receptor Antagonist (IL1Ra) Axis in Prostate Cancer CD133+ Stem/Progenitor Cells to Battle Prostate Cancer. Journal of Biological Chemistry, 2013, 288, 16476-16483.	3.4	49
144	Androgen receptor promotes the migration and invasion of upper urinary tract urothelial carcinoma cells through the upregulation of MMP-9 and COX-2. Oncology Reports, 2013, 30, 979-985.	2.6	15

#	Article	IF	Citations
145	Androgen receptor decreases the cytotoxic effects of chemotherapeutic drugs in upper urinary tract urothelial carcinoma cells. Oncology Letters, 2013, 5, 1325-1330.	1.8	9
146	Epidermal growth factor enhances androgen receptor-mediated bladder cancer progression and invasion via potentiation of AR transactivation. Oncology Reports, 2013, 30, 2917-2922.	2.6	23
147	Androgen Receptor (AR) Pathophysiological Roles in Androgen Related Diseases in Skin, Metabolism Syndrome, Bone/Muscle and Neuron/Immune Systems: Lessons Learned from Mice Lacking AR in Specific Cells. Nuclear Receptor Signaling, 2013, 11, nrs.11001.	1.0	69
148	Testosterone Delivered with a Scaffold Is as Effective as Bone Morphologic Protein-2 in Promoting the Repair of Critical-Size Segmental Defect of Femoral Bone in Mice. PLoS ONE, 2013, 8, e70234.	2.5	22
149	Up-Regulation of SOX9 in Sertoli Cells from Testiculopathic Patients Accounts for Increasing Anti-Mullerian Hormone Expression via Impaired Androgen Receptor Signaling. PLoS ONE, 2013, 8, e76303.	2.5	27
150	Androgen Receptor-Regulated Genes in Prostate Cancer Initiation Versus Metastasis. , 2013, , 155-176.		0
151	Targeting Androgen Receptor to Suppress Macrophage-induced EMT and Benign Prostatic Hyperplasia (BPH) Development. Molecular Endocrinology, 2012, 26, 1707-1715.	3.7	70
152	Suppressed Prostate Epithelial Development with Impaired Branching Morphogenesis in Mice Lacking Stromal Fibromuscular Androgen Receptor. Molecular Endocrinology, 2012, 26, 52-66.	3.7	55
153	Suppressor role of androgen receptor in proliferation of prostate basal epithelial and progenitor cells. Journal of Endocrinology, 2012, 213, 173-182.	2.6	39
154	Increased Infiltrated Macrophages in Benign Prostatic Hyperplasia (BPH). Journal of Biological Chemistry, 2012, 287, 18376-18385.	3.4	61
155	Androgen Receptor Influences on Body Defense System via Modulation of Innate and Adaptive Immune Systems. American Journal of Pathology, 2012, 181, 1504-1512.	3.8	145
156	Targeting the Unique Methylation Pattern of Androgen Receptor (AR) Promoter in Prostate Stem/Progenitor Cells with 5-Aza-2â€²-deoxycytidine (5-AZA) Leads to Suppressed Prostate Tumorigenesis. Journal of Biological Chemistry, 2012, 287, 39954-39966.	3.4	58
157	ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors. Neoplasia, 2012, 14, 74-IN12.	5.3	123
158	Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. Cancer Letters, 2012, 316, 11-22.	7.2	61
159	Reduced osteoblast activity in the mice lacking TR4 nuclear receptor leads to osteoporosis. Reproductive Biology and Endocrinology, 2012, 10, 43.	3.3	23
160	Androgen and androgen receptor signals jamming monocyte/macrophage functions in premalignant		

#	Article	IF	Citations
163	The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells. Prostate, 2012, 72, 803-816.	2.3	22
164	The role of androgen and androgen receptor in skin-related disorders. Archives of Dermatological Research, 2012, 304, 499-510.	1.9	124
165	Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of proâ€inflammatory cytokines/chemokines. EMBO Molecular Medicine, 2012, 4, 791-807.	6.9	70
166	Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology, 2012, 56, 176-185.	7.3	130
167	Deficiency in TR4 nuclear receptor abrogates Gadd45a expression and increases cytotoxicity induced by ionizing radiation. Cellular and Molecular Biology Letters, 2012, 17, 309-22.	7.0	17
168	Identification of testosterone-/androgen receptor-regulated genes in mouse Sertoli cells. Asian Journal of Andrology, 2012, 14, 294-300.	1.6	30
169	Tissue-Specific Knockout of Androgen Receptor in Mice. Methods in Molecular Biology, 2011, 776, 275-293.	0.9	8
170	The reduced trabecular bone mass of adult ARKO male mice results from the decreased osteogenic differentiation of bone marrow stroma cells. Biochemical and Biophysical Research Communications, 2011, 411, 477-482.	2.1	19
171	Increased CK5/CK8-Positive Intermediate Cells with Stromal Smooth Muscle Cell Atrophy in the Mice Lacking Prostate Epithelial Androgen Receptor. PLoS ONE, 2011, 6, e20202.	2.5	21
172	TR4 activates FATP1 gene expression to promote lipid accumulation in 3T3-L1 adipocytes. FEBS Letters, 2011, 585, 2763-2767.	2.8	29
173	The roles of testicular nuclear receptor 4 (TR4) in male fertility-priapism and sexual behavior defects in TR4 knockout mice. Reproductive Biology and Endocrinology, 2011, 9, 138.	3.3	11
174	Altered prostate epithelial development and IGFâ€1 signal in mice lacking the androgen receptor in stromal smooth muscle cells. Prostate, 2011, 71, 517-524.	2.3	55
175	Metformin Inhibits Nuclear Receptor TR4â€“Mediated Hepatic Stearoyl-CoA Desaturase 1 Gene Expression With Altered Insulin Sensitivity. Diabetes, 2011, 60, 1493-1503.	0.6	69
176	Increased Acetylation in the DNA-binding Domain of TR4 Nuclear Receptor by the Coregulator ARA55 Leads to Suppression of TR4 Transactivation. Journal of Biological Chemistry, 2011, 286, 21129-21136.	3.4	16
177	Testicular Nuclear Receptor 4 (TR4) Regulates UV Light-induced Responses via Cockayne Syndrome B Protein-mediated Transcription-coupled DNA Repair. Journal of Biological Chemistry, 2011, 286, 38103-38108.	3.4	11
178	Mice Lacking TR4 Nuclear Receptor Develop Mitochondrial Myopathy with Deficiency in Complex I. Molecular Endocrinology, 2011, 25, 1301-1310.	3.7	19
179	Premature aging with impaired oxidative stress defense in mice lacking TR4. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E91-E98.	3.5	31
180	Involvement of Interleukin-6 and Androgen Receptor Signaling in Pancreatic Cancer. Genes and Cancer, 2010, 1, 859-867.	1.9	50

#	Article	IF	Citations
181	Tumor suppressor PAX6 functions as androgen receptor Coâ€repressor to inhibit prostate cancer growth. Prostate, 2010, 70, 190-199.	2.3	45
182	Androgen Receptor Promotes Hepatitis B Virusâ€“Induced Hepatocarcinogenesis Through Modulation of Hepatitis B Virus RNA Transcription. Science Translational Medicine, 2010, 2, 32ra35.	12.4	171
183	Physiological Functions of TR2 and TR4 Orphan Nuclear Receptor. , 2010, , 327-343.		1
184	Defects of Prostate Development and Reproductive System in the Estrogen Receptor-Î± Null Male Mice. Endocrinology, 2009, 150, 251-259.	2.8	67
185	TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13353-13358.	7.1	94
186	Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-Î± expression. Journal of Clinical Investigation, 2009, 119, 3739-3751.	8.2	169
187	Roles of Testicular Orphan Nuclear Receptors 2 and 4 in Early Embryonic Development and Embryonic Stem Cells. Endocrinology, 2009, 150, 2454-2462.	2.8	37
188	Susceptibility to Autoimmunity and B Cell Resistance to Apoptosis in Mice Lacking Androgen Receptor in B Cells. Molecular Endocrinology, 2009, 23, 444-453.	3.7	68
189	Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor. Journal of Experimental Medicine, 2009, 206, 1181-1199.	8.5	119
190	Activation of TR4 orphan nuclear receptor gene promoter by cAMP/PKA and C/EBP signaling. Endocrine, 2009, 36, 211-217.	2.3	20
191	The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian Journal of Andrology, 2009, 11, 39-48.	1.6	28
192	Androgen Receptor Roles in Spermatogenesis and Fertility: Lessons from Testicular Cell-Specific Androgen Receptor Knockout Mice. Endocrine Reviews, 2009, 30, 119-132.	20.1	375
193	Differential Roles of Androgen Receptor in Prostate Development and Cancer Progression. , 2009, , 73-89.		3
194	IL1 Dual Roles of Androgen Receptor Challenge the Androgen Deprivation Therapy of Prostate Cancer(The 97th Annual Meeting of the Japanese Urological Association). Japanese Journal of Urology, 2009, 100, 40.	0.1	0
195	The roles of testicular orphan nuclear receptor 4 (TR4) in cerebellar development. Cerebellum, 2008, 7, 9-17.	2.5	21
196	A new prostate cancer therapeutic approach: Combination of androgen ablation with COXâ€2 inhibitor. International Journal of Cancer, 2008, 123, 195-201.	5.1	34
197	Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology, 2008, 47, 1924-1935.	7.3	173
198	Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular Carcinoma. Gastroenterology, 2008, 135, 947-955.e5.	1.3	213

#	Article	IF	Citations
199	Actin associated proteins function as androgen receptor coregulators: An implication of androgen receptor's roles in skeletal muscle. Journal of Steroid Biochemistry and Molecular Biology, 2008, 111, 157-163.	2.5	20
200	Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12188-12193.	7.1	134
201	Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12182-12187.	7.1	226
202	Tissue Prostate-Specific Antigen Facilitates Refractory Prostate Tumor Progression via Enhancing ARA70-Regulated Androgen Receptor Transactivation. Cancer Research, 2008, 68, 7110-7119.	0.9	66
203	Altered TNSALP Expression and Phosphate Regulation Contribute to Reduced Mineralization in Mice Lacking Androgen Receptor. Molecular and Cellular Biology, 2008, 28, 7354-7367.	2.3	23
204	Oxidative Stress Stimulates Testicular Orphan Receptor 4 through Forkhead Transcription Factor Forkhead Box O3a. Endocrinology, 2008, 149, 3490-3499.	2.8	22
205	Subfertility with Defective Folliculogenesis in Female Mice Lacking Testicular Orphan Nuclear Receptor 4. Molecular Endocrinology, 2008, 22, 858-867.	3.7	35
206	Hyperleptinemia without Obesity in Male Mice Lacking Androgen Receptor in Adipose Tissue. Endocrinology, 2008, 149, 2361-2368.	2.8	63
207	Androgen Receptor in Prostate Cancer Progression. , 2008, , 129-146.		1
208	The roles of testicular orphan nuclear receptor 4 (TR4) in cerebellar development. Cerebellum, 2008, 7, 1-9.	2.5	1
209	Promotion of Bladder Cancer Development and Progression by Androgen Receptor Signals. Journal of the National Cancer Institute, 2007, 99, 558-568.	6.3	353
210	Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12679-12684.	7.1	182
211	Loss of Testicular Orphan Receptor 4 Impairs Normal Myelination in Mouse Forebrain. Molecular Endocrinology, 2007, 21, 908-920.	3.7	17
212	Transgelin Functions as a Suppressor via Inhibition of ARA54-Enhanced Androgen Receptor Transactivation and Prostate Cancer Cell Growth. Molecular Endocrinology, 2007, 21, 343-358.	3.7	76
213	Suppression of Androgen Receptor Transactivation and Prostate Cancer Cell Growth by Heterogeneous Nuclear Ribonucleoprotein A1 via Interaction with Androgen Receptor Coregulator ARA54. Endocrinology, 2007, 148, 1340-1349.	2.8	19
214	Loss of TR4 Orphan Nuclear Receptor Reduces Phosphoenolpyruvate Carboxykinaseâ€“Mediated Gluconeogenesis. Diabetes, 2007, 56, 2901-2909.	0.6	65
215	TR4 orphan nuclear receptor functions as an apoptosis modulator via regulation of Bcl-2 gene expression. Biochemical and Biophysical Research Communications, 2007, 361, 323-328.	2.1	20
216	ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nature Medicine, 2007, 13, 348-353.	30.7	147

#	Article	IF	Citations
217	Abnormal cerebellar cytoarchitecture and impaired inhibitory signaling in adult mice lacking TR4 orphan nuclear receptor. Brain Research, 2007, 1168, 72-82.	2.2	14
218	Infertility with defective spermatogenesis and steroidogenesis in male mice lacking androgen receptor in Leydig cells. Endocrine, 2007, 32, 96-106.	2.2	126
219	Stage dependent and androgen inductive expression of orphan receptor TR4 in rat testis. Biochemical and Biophysical Research Communications, 2006, 341, 464-469.	2.1	9
220	Transactivation of the proximal promoter of human oxytocin gene by TR4 orphan receptor. Biochemical and Biophysical Research Communications, 2006, 351, 204-208.	2.1	12
221	Androgen Receptor in Sertoli Cell Is Essential for Germ Cell Nursery and Junctional Complex Formation in Mouse Testes. Endocrinology, 2006, 147, 5624-5633.	2.8	177
222	Differential effects of spermatogenesis and fertility in mice lacking androgen receptor in individual testis cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18975-18980.	7.1	173
223	Oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17718-17723.	7.1	126
224	HORMONAL THERAPY FOR PROSTATE CANCER: CLINICAL AND EXPERIMENTAL EVIDENCE. , 2005, , 1-32.		0
225	Identification of steroid derivatives that function as potent antiandrogens. International Journal of Cancer, 2005, 117, 866-872.	5.1	13
226	Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. Molecular Carcinogenesis, 2005, 44, 1-10.	2.7	60
227	Androgen receptor corepressors: An overview. Prostate, 2005, 63, 117-130.	2.3	98
228	Deficits in Motor Coordination with Aberrant Cerebellar Development in Mice Lacking Testicular Orphan Nuclear Receptor 4. Molecular and Cellular Biology, 2005, 25, 2722-2732.	2.3	73
229	Androgen Receptor (AR) NH2- and COOH-Terminal Interactions Result in the Differential Influences on the AR-Mediated Transactivation and Cell Growth. Molecular Endocrinology, 2005, 19, 350-361.	3.7	62
230	Insulin and Leptin Resistance With Hyperleptinemia in Mice Lacking Androgen Receptor. Diabetes, 2005, 54, 1717-1725.	0.6	159
231	Induction of Androgen Receptor Expression by Phosphatidylinositol 3-Kinase/Akt Downstream Substrate, FOXO3a, and Their Roles in Apoptosis of LNCaP Prostate Cancer Cells. Journal of Biological Chemistry, 2005, 280, 33558-33565.	3.4	122
232	Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?. Nature Clinical Practice Oncology, 2005, 2, 236-237.	4.3	17
233	Induction of apolipoprotein E expression by TR4 orphan nuclear receptor via 5â€² proximal promoter region. Biochemical and Biophysical Research Communications, 2005, 328, 85-90.	2.1	23
234	Suppression of Androgen Receptor-mediated Transactivation and Cell Growth by the Glycogen Synthase Kinase 3Î² in Prostate Cells. Journal of Biological Chemistry, 2004, 279, 32444-32452.	3.4	86

#	Article	IF	Citations
235	ARA67/PAT1 Functions as a Repressor To Suppress Androgen Receptor Transactivation. Molecular and Cellular Biology, 2004, 24, 1044-1057.	2.3	33
236	Growth retardation and abnormal maternal behavior in mice lacking testicular orphan nuclear receptor 4. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15058-15063.	7.1	88
237	Functional Domain and Motif Analyses of Androgen Receptor Coregulator ARA70 and Its Differential Expression in Prostate Cancer. Journal of Biological Chemistry, 2004, 279, 33438-33446.	3.4	82
238	Human Checkpoint Protein hRad9 Functions as a Negative Coregulator To Repress Androgen Receptor Transactivation in Prostate Cancer Cells. Molecular and Cellular Biology, 2004, 24, 2202-2213.	2.3	55
239	Androgen Receptor Coregulators in Prostate Cancer. Clinical Cancer Research, 2004, 10, 2208-2219.	7.0	98
240	Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11209-11214.	7.1	270
241	Targeted Inactivation of Testicular Nuclear Orphan Receptor 4 Delays and Disrupts Late Meiotic Prophase and Subsequent Meiotic Divisions of Spermatogenesis. Molecular and Cellular Biology, 2004, 24, 5887-5899.	2.3	60
242	Androgen Receptor Regulates Expression of Skeletal Muscleâ€“Specific Proteins and Muscle Cell Types. Endocrine, 2004, 25, 27-32.	2.2	50
243	Nongenomic Androgen Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway in MC3T3-E1 Osteoblasts. Journal of Bone and Mineral Research, 2004, 19, 1181-1190.	2.8	104
244	Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells. Prostate, 2004, 60, 61-67.	2.3	46
245	Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate, 2004, 61, 332-353.	2.3	279
246	Molecular basis for the antiandrogen withdrawal syndrome. Journal of Cellular Biochemistry, 2004, 91, 3-12.	2.6	85
247	Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6876-6881.	7.1	405
248	Androgen Receptor in Prostate Cancer. Endocrine Reviews, 2004, 25, 276-308.	20.1	1,475
249	Actin monomer enhances supervillin-modulated androgen receptor transactivation. Biochemical and Biophysical Research Communications, 2004, 319, 393-393.	2.1	0
250	Androgen suppresses PML protein expression in prostate cancer CWR22R cells. Biochemical and Biophysical Research Communications, 2004, 314, 69-75.	2.1	15
251	Actin monomer enhances supervillin-modulated androgen receptor transactivation. Biochemical and Biophysical Research Communications, 2004, 319, 393-396.	2.1	16
252	Modulation of the retinoic acid-induced cell apoptosis and differentiation by the human TR4 orphan nuclear receptor. Biochemical and Biophysical Research Communications, 2004, 323, 876-883.	2.1	13

#	Article	IF	Citations
253	Induction and Repression of Peroxisome Proliferator-Activated Receptor Î± Transcription by Coregulator ARA70. Endocrine, 2003, 21, 139-146.	2.2	9
254	Antitumor agents 222. â€ â€For Part 221, see ref 1. Synthesis and anti-androgen activity of new diarylheptanoids. Bioorganic and Medicinal Chemistry, 2003, 11, 5083-5090.	3.0	44
255	TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3. Prostate, 2003, 57, 129-133.	2.3	26
256	Differential and bi-directional regulation between TR2/TR4 orphan nuclear receptors and a specific ligand mediated-peroxisome proliferator-activated receptor Î± in human HaCaT keratinocytes. Journal of Dermatological Science, 2003, 31, 65-71.	1.9	3
257	The Use of Phage Display Technique for the Isolation of Androgen Receptor Interacting Peptides with (F/W)XXL(F/W) and FXXLY New Signature Motifs. Journal of Biological Chemistry, 2003, 278, 23691-23698.	3.4	75
258	The second largest subunit of RNA polymerase II interacts with and enhances transactivation of androgen receptor. Biochemical and Biophysical Research Communications, 2003, 302, 162-169.	2.1	11
259	Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochemical and Biophysical Research Communications, 2003, 305, 462-469.	2.1	150
260	Molecular communication between androgen receptor and general transcription machinery. Journal of Steroid Biochemistry and Molecular Biology, 2003, 84, 41-49.	2.5	83
261	Identification of a Novel Testicular Orphan Receptor-4 (TR4)-associated Protein as Repressor for the Selective Suppression of TR4-mediated Transactivation. Journal of Biological Chemistry, 2003, 278, 7709-7717.	3.4	21
262	3Â-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4440-4444.	7.1	17
263	Disruption of TR4 Orphan Nuclear Receptor Reduces the Expression of Liver Apolipoprotein E/C-I/C-II Gene Cluster. Journal of Biological Chemistry, 2003, 278, 46919-46926.	3.4	43
264	Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5124-5129.	7.1	58
265	Suppression Versus Induction of Androgen Receptor Functions by the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer LNCaP Cells with Different Passage Numbers. Journal of Biological Chemistry, 2003, 278, 50902-50907.	3.4	170
266	Abnormal Mammary Gland Development and Growth Retardation in Female Mice and MCF7 Breast Cancer Cells Lacking Androgen Receptor. Journal of Experimental Medicine, 2003, 198, 1899-1908.	8.5	138
267	APPL Suppresses Androgen Receptor Transactivation via Potentiating Akt Activity. Journal of Biological Chemistry, 2003, 278, 16820-16827.	3.4	52
268	Reducing the Agonist Activity of Antiandrogens by a Dominant-negative Androgen Receptor Coregulator ARA70 in Prostate Cancer Cells. Journal of Biological Chemistry, 2003, 278, 19619-19626.	3.4	39
269	Suppression of Hepatitis B Virus Core Promoter by the Nuclear Orphan Receptor TR4. Journal of Biological Chemistry, 2003, 278, 9353-9360.	3.4	28
270	Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Research, 2003, 63, 4888-94.	0.9	95

#	Article	IF	Citations
271	Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Research, 2003, 63, 7106-12.	0.9	46
272	Suppression of Estrogen Receptor-mediated Transcription and Cell Growth by Interaction with TR2 Orphan Receptor. Journal of Biological Chemistry, 2002, 277, 33571-33579.	3.4	37
273	Differential Modulation of Androgen Receptor-mediated Transactivation by Smad3 and Tumor Suppressor Smad4. Journal of Biological Chemistry, 2002, 277, 43749-43756.	3.4	93
274	Androgen Receptor (AR) Coregulators: An Overview. Endocrine Reviews, 2002, 23, 175-200.	20.1	767
275	Modulation of Estrogen Receptor-mediated Transactivation by Orphan Receptor TR4 in MCF-7 Cells. Journal of Biological Chemistry, 2002, 277, 14622-14628.	3.4	47
276	Proteasome Activity Is Required for Androgen Receptor Transcriptional Activity via Regulation of Androgen Receptor Nuclear Translocation and Interaction with Coregulators in Prostate Cancer Cells. Journal of Biological Chemistry, 2002, 277, 36570-36576.	3.4	127
277	Androgen Receptor Acetylation Governs trans Activation and MEKK1-Induced Apoptosis without Affecting In Vitro Sumoylation and trans -Repression Function. Molecular and Cellular Biology, 2002, 22, 3373-3388.	2.3	155
278	Suppression of Androgen Receptor Transactivation by Pyk2 via Interaction and Phosphorylation of the ARA55 Coregulator. Journal of Biological Chemistry, 2002, 277, 15426-15431.	3.4	46
279	Supervillin associates with androgen receptor and modulates its transcriptional activity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 661-666.	7.1	99
280	Repression of Glucagon Gene Transcription by Peroxisome Proliferator-activated Receptor Î³ through Inhibition of Pax6 Transcriptional Activity. Journal of Biological Chemistry, 2002, 277, 1941-1948.	3.4	25
281	A Dominant-negative Mutant of Androgen Receptor Coregulator ARA54 Inhibits Androgen Receptor-mediated Prostate Cancer Growth. Journal of Biological Chemistry, 2002, 277, 4609-4617.	3.4	57
282	The Roles of Androgen Receptors and Androgen-Binding Proteins in Nongenomic Androgen Actions. Molecular Endocrinology, 2002, 16, 2181-2187.	3.7	476
283	Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13498-13503.	7.1	591
284	Antitumor Agents. 217.â€Curcumin Analogues as Novel Androgen Receptor Antagonists with Potential as Anti-Prostate Cancer Agents. Journal of Medicinal Chemistry, 2002, 45, 5037-5042.	6.4	243
285	Recent advances in the TR2 and TR4 orphan receptors of the nuclear receptor superfamily. Journal of Steroid Biochemistry and Molecular Biology, 2002, 81, 291-308.	2.5	83
286	Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO Journal, 2002, 21, 4037-4048.	7.8	387
287	Androgen Receptor (AR) Coregulators: An Overview. , 2002, 23, 175-200.		217
288	Androgen Receptor Interacting Proteins: Co-Activators And Co-Repressors. , 2002, , 91-138.		0

#	Article	IF	Citations
289	Interaction of Cell Cycle Regulatory Proteins with the Androgen Receptor. , 2002, , 223-238.		0
290	The Expanded Poly-Q Length Within AR and AR Coregulator AIB1 and Their Clinical Implications. , 2002, , 245-264.		0
291	Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Research, 2002, 62, 6039-44.	0.9	42
292	TR4 Orphan Receptor Represses the Human Steroid 21-Hydroxylase Gene Expression through the Monomeric AGGTCA Motif. Biochemical and Biophysical Research Communications, 2001, 285, 1361-1368.	2.1	17
293	Localization of androgen receptor expression in human bone marrow. Journal of Pathology, 2001, 193, 361-366.	4.5	129
294	Quercetin Cumulatively Enhances Copper Induction of Metallothionein in Intestinal Cells. Biological Trace Element Research, 2001, 84, 001-010.	3.5	15
295	Role of Chaperones in Nuclear Translocation. Endocrine, 2001, 14, 143-150.	2.2	32
296	Identification and Characterization of a Novel Androgen Receptor Coregulator ARA267-Î± in Prostate Cancer Cells. Journal of Biological Chemistry, 2001, 276, 40417-40423.	3.4	67
297	Androgen Receptor Interacts with the Positive Elongation Factor P-TEFb and Enhances the Efficiency of Transcriptional Elongation. Journal of Biological Chemistry, 2001, 276, 9978-9984.	3.4	118
298	Feedback Regulation between Orphan Nuclear Receptor TR2 and Human Papilloma Virus Type 16. Journal of Biological Chemistry, 2001, 276, 27316-27321.	3.4	7
299	Differential regulation of testosterone vs. 5alpha-dihydrotestosterone by selective androgen response elements. Molecular and Cellular Biochemistry, 2000, 206, 169-175.	3.1	29
300	Isolation and Characterization of the Androgen Receptor Mutants with Divergent Transcriptional Activity in Response to Hydroxyflutamide. Endocrine, 2000, 12, 69-76.	2.2	12
301	Identification of an Essential cis-acting Element (TR2-PACE) in the 5' Promoter of Human TR2 Orphan Receptor Gene. Endocrine, 2000, 12, 89-98.	2.2	9
302	From Androgen Receptor to the General Transcription Factor TFIIH. Journal of Biological Chemistry, 2000, 275, 9308-9313.	3.4	102
303	The p53/Retinoblastoma-mediated Repression of Testicular Orphan Receptor-2 in the Rhesus Monkey with Cryptorchidism. Journal of Biological Chemistry, 2000, 275, 23877-23883.	3.4	30
304	Expression of the orphan receptor TR4 during brain development of the rat. Molecular Brain Research, 2000, 77, 104-110.	2.3	20
305	Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Research, 1999, 27, 2165-2174.	14.5	97
306	Identification of ARA70 as a Ligand-enhanced Coactivator for the Peroxisome Proliferator-activated Receptor Î³. Journal of Biological Chemistry, 1999, 274, 16147-16152.	3.4	120

#	Article	IF	Citations
307	The Linkage of Kennedy's Neuron Disease to ARA24, the First Identified Androgen Receptor Polyglutamine Region-associated Coactivator. Journal of Biological Chemistry, 1999, 274, 20229-20234.	3.4	198
308	Cloning and Characterization of Androgen Receptor Coactivator, ARA55, in Human Prostate. Journal of Biological Chemistry, 1999, 274, 8316-8321.	3.4	255
309	Cloning and Characterization of Human Prostate Coactivator ARA54, a Novel Protein That Associates with the Androgen Receptor. Journal of Biological Chemistry, 1999, 274, 8570-8576.	3.4	196
310	Differential Regulation of Direct Repeat 3 Vitamin D3and Direct Repeat 4 Thyroid Hormone Signaling Pathways by the Human TR4 Orphan Receptor. Journal of Biological Chemistry, 1999, 274, 16198-16205.	3.4	48
311	Induction of TR4 Orphan Receptor by Retinoic Acid in Human HaCaT Keratinocytes. Journal of Investigative Dermatology, 1999, 112, 426-431.	0.7	13
312	Identification of the histamine H1 receptor gene as a differentially repressed target of the human TR2 orphan receptor. Molecular and Cellular Biochemistry, 1999, 194, 199-207.	3.1	13
313	Androgen effects on the solubility and conformational change of the androgen receptor in baculovirus expression system. , 1999, 195, 19-23.		1
314	Monoclonal anti-androgen receptor antibodies: production, characterization and potential diagnostic applications. Molecular and Cellular Biochemistry, 1999, 201, 131-140.	3.1	1
315	Differential Induction of Androgen Receptor Transactivation by Different Androgen Receptor Coactivators in Human Prostate Cancer DU145 Cells. Endocrine, 1999, 11, 195-202.	2.2	68
316	Roles of Testosterone in the Growth of Keratinocytes Through Bald Frontal Dermal Papilla Cells. Endocrine, 1999, 11, 321-328.	2.2	19
317	Transcriptional activation of human TR3/nur77 gene expression by human T-lymphotropic virus type I Tax protein through two AP-1-like elements. Journal of General Virology, 1999, 80, 3073-3081.	2.9	25
318	Differential Induction of the Androgen Receptor Transcriptional Activity by Selective Androgen Receptor Coactivators.. Keio Journal of Medicine, 1999, 48, 87-92.	1.1	48
319	Thyroid hormone direct repeat 4 response element is a positive regulatory element for the human TR2 orphan receptor, a member of steroid receptor superfamily. , 1998, 189, 195-200.		15
320	The Genomic Structure and Chromosomal Location of the Human TR2 Orphan Receptor, a Member of the Steroid Receptor Superfamily. Endocrine, 1998, 8, 123-134.	2.2	9
321	TR4 Orphan Receptor Crosstalks to Chicken Ovalbumin Upstream Protein-Transcription Factor and Thyroid Hormone Receptor to Induce the Transcriptional Activity of the Human Immunodeficiency Virus Type 1 Long-Terminal Repeat. Endocrine, 1998, 8, 169-176.	2.2	15
322	Induction of an Intronic Enhancer of the Human Ciliary Neurotrophic Factor Receptor (CNTFRÎ±) Gene by the TR3 Orphan Receptor. Endocrine, 1998, 9, 27-32.	2.2	5
323	Evaluation of RU58841 as an Anti-Androgen in Prostate PC3 Cells and a Topical Anti-Alopecia Agent in the Bald Scalp of Stumptailed Macaques. Endocrine, 1998, 9, 39-44.	2.2	18
324	Ontogeny and Autoregulation of Androgen Receptor mRNA Expression in the Nervous System. Endocrine, 1998, 9, 79-88.	2.2	41

#	Article	IF	Citations
325	Retinoblastoma, a Tumor Suppressor, Is a Coactivator for the Androgen Receptor in Human Prostate Cancer DU145 Cells. Biochemical and Biophysical Research Communications, 1998, 248, 361-367.	2.1	123
326	A Bidirectional Regulation between the TR2/TR4 Orphan Receptors (TR2/TR4) and the Ciliary Neurotrophic Factor (CNTF) Signaling Pathway. Journal of Biological Chemistry, 1998, 273, 20877-20885.	3.4	34
327	Antisense TR3 Orphan Receptor Can Increase Prostate Cancer Cell Viability with Etoposide Treatment¹. Endocrinology, 1998, 139, 2329-2334.	2.8	70
328	Negative Feedback Control of the Retinoid-Retinoic Acid/Retinoid X Receptor Pathway by the Human TR4 Orphan Receptor, a Member of the Steroid Receptor Superfamily. Journal of Biological Chemistry, 1998, 273, 13437-13443.	3.4	58
329	Inhibition of Hair Growth by Testosterone in the Presence of Dermal Papilla Cells from the Frontal Bald Scalp of the Postpubertal Stumptailed Macaque1. Endocrinology, 1997, 138, 356-361.	2.8	46
330	Transcriptional Up-Regulation of the Human Androgen Receptor by Androgen in Bone Cells*. Endocrinology, 1997, 138, 2291-2300.	2.8	95
331	Induction of the Intronic Enhancer of the Human Ciliary Neurotrophic Factor Receptor (CNTFRÃ) Gene by the TR4 Orphan Receptor. Journal of Biological Chemistry, 1997, 272, 3109-3116.	3.4	57
332	Identification of Direct Repeat 4 as a Positive Regulatory Element for the Human TR4 Orphan Receptor. Journal of Biological Chemistry, 1997, 272, 12215-12220.	3.4	56
333	Hydroxyflutamide may not always be a pure antiandrogen. Lancet, The, 1997, 349, 852-853.	13.7	70
334	Identification of the Human Aldolase A Gene as the First Induced Target for the TR2 Orphan Receptor, a Member of the Steroid Hormone Receptor Superfamily. Biochemical and Biophysical Research Communications, 1997, 235, 205-211.	2.1	11
335	Transcriptional Up-Regulation of the Human Androgen Receptor by Androgen in Bone Cells. Endocrinology, 1997, 138, 2291-2300.	2.8	32
336	p53 Is a Mediator for Radiation-repressed Human TR2 Orphan Receptor Expression in MCF-7 Cells, a New Pathway from Tumor Suppressor to Member of the Steroid Receptor Superfamily. Journal of Biological Chemistry, 1996, 271, 14649-14652.	3.4	43
337	Suppression of the Human Erythropoietin Gene Expression by the TR2 Orphan Receptor, a Member of the Steroid Receptor Superfamily. Journal of Biological Chemistry, 1996, 271, 10405-10412.	3.4	36
338	Multiple Functions of the TR2-11 Orphan Receptor in Modulating Activation of Two Key Cis-acting Elements Involved in the Retinoic Acid Signal Transduction System. Journal of Biological Chemistry, 1995, 270, 30121-30128.	3.4	51
339	Suppression of Gene Expression on the Simian Virus 40 Major Late Promoter by Human TR4 Orphan Receptor. Journal of Biological Chemistry, 1995, 270, 30129-30133.	3.4	50
340	Identification of Human TR2 Orphan Receptor Response Element in the Transcriptional Initiation Site of the Simian Virus 40 Major Late Promoter. Journal of Biological Chemistry, 1995, 270, 5434-5440.	3.4	58
341	Androgen Receptor: An Overview. Critical Reviews in Eukaryotic Gene Expression, 1995, 5, 97-125.	0.9	260
342	Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene.. Molecular Endocrinology, 1993, 7, 23-36.	3.7	238

#	Article	IF	Citations
343	Autoregulation of androgen receptor expression in rodent prostate: Immunohistochemical and in situ hybridization analysis. Biochemical and Biophysical Research Communications, 1991, 177, 488-496.	2.1	83